

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

20 Jun 2026

### Evaluation of the circadian rhythm disturbance impacts on the human reward system, impulsivity and cognitive performance

#### Protocol summary

Cognitive functions, reward system, mood rhythmicity, substance use readiness, impulsivity

#### Study aim

The general aim of this study was to determine the effect of circadian rhythm disturbance on human reward system, impulsivity and cognitive function and the specific objectives are as follows Determination of circadian rhythm disorders in the subjects Determining the incidence of impulsivity in the subjects Determining the reward system in the subjects Determining cognitive function in the subjects Determining the reward circuit in the subjects Determining readiness for substance use and addictive behaviors

#### Design

Double-blind randomized controlled trial, the sample size in this study was selected with 80% power, significance level 0.05 and impact size 0.9 (17 people in each group) in the total sample size of 34, participants as Random blocks will be divided into intervention and control groups.

#### Settings and conduct

This study will be performed on the research site of Shahrood University of Medical Sciences for eleven days and during the experimental period, variables such as ambient light intensity, eating time and sleeping time will change in the experimental group but will not change in the control group. In this study, participants and analysts will not be aware of the study results of groups

#### Participants/Inclusion and exclusion criteria

inclusion: Male right handed Age category between 18 and 25 years Regular rhythm of sleep and wakefulness in the past month Exclusion: Having a general medical disorder that endangers a person's health during the experiment

#### Intervention groups

The duration of this study is eleven days and variables such as ambient light intensity, eating and sleeping time as previously described will change for the participants of the experimental group and for the participants of the group. Control will remain unchanged.

#### Main outcome variables

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20210202050223N1**

Registration date: **2021-04-24, 1400/02/04**

Registration timing: **prospective**

Last update: **2021-04-24, 1400/02/04**

Update count: **0**

##### Registration date

2021-04-24, 1400/02/04

##### Registrant information

##### Name

Mohammad Niroumand Sarvandani

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 34 3245 4926

##### Email address

m.niroumand@shmu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-05-13, 1400/02/23

##### Expected recruitment end date

2021-05-25, 1400/03/04

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of the circadian rhythm disturbance impacts on the human reward system, impulsivity and cognitive performance

**Public title**

the effect of circadian rhythm disturbance on reward circuit and psychological functions

**Purpose**

Prevention

**Inclusion/Exclusion criteria****Inclusion criteria:**

Male gender right handed Age range between 18 and 25 years Regular rhythm of sleep and wakefulness in the past month (8 to 10) hours of sleep a night

**Exclusion criteria:**

Having a history of psychiatric disorder Having a history of substance abuse Use of psychiatric drugs Having a general medical disorder that endangers participants health during the test Having a history of brain trauma Having a metal body in the body, including platinum, fragments or iron particles Having an irregular rhythm of sleeping and waking in the last month (8 to 10) hours of sleep at night (night shift work) Having body mass index higher than 30

**Age**

From **18 years** old to **25 years** old

**Gender**

Male

**Phase**

N/A

**Groups that have been masked**

- Participant
- Outcome assessor
- Data analyser

**Sample size**

Target sample size: **34**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

To equal the sample size in the two groups, the block method with a volume of 4 is used. For this purpose, 6 to four blocks will be created as follows 1- AABB 2- ABAB 3- ABBA 4- BBAA 5- BABA 6- BAAB Where A is for the intervention group and B is for the control group The random assignment will be done in such a way that a random number will be created in Excel from 0 to 9 first. Depending on which block the random number belongs to, the sequence of that block is used to assign the subjects to the control and intervention group. For example, if the random number generated is 6, the first person will be assigned to group B, the second person to group A, the third person to group A, and the fourth person to group B. To reach the calculated sample size, the random number creation will be repeated 9 times. Because each time the task is assigned, four diseases are identified. It should be noted that if the random number generated is 7, 8, 9 and 0, it will be ignored.

Envelopes in which the specified group is placed are used to conceal the allocation. Envelopes are numbered. After filling in the basic information of the people, an envelope is opened according to the word order of the people and the person is assigned to the desired group. To do this, 34 envelopes will be ready and individuals will be assigned to two groups. The methodology consultant determines the allocation sequence. The registration of participants and their entry according to the entry and exit criteria and obtaining informed consent is the responsibility of a trained psychologist. Then, if they are eligible, it assigns them to groups based on closed envelopes.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

In this study, participants and analysts will not be aware of the results of the study. Also, in all outcome assessments conducted by questionnaires or interviews by a psychologist colleague, the research colleagues are unaware of how the participants are placed in the groups.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Shahroud university of medical science

**Street address**

Shahroud University of Medical Sciences and Health Services, Hafte Tir Square, Shahroud, Iran

**City**

shahroud

**Province**

Semnan

**Postal code**

۳۶۱۴۷-۷۳۹۴۷

**Approval date**

2021-02-07, 1399/11/19

**Ethics committee reference number**

IR.SHMU.REC.1399.170

**Health conditions studied****1****Description of health condition studied**

circadian rhythm disorder (shift work type)

**ICD-10 code**

G47.26

**ICD-10 code description**

Circadian rhythm sleep disorder, shift work type

**Primary outcomes****1****Description**

Impulsivity score in Bart's Impulsivity Questionnaire

**Timepoint**

Beginning of the intervention (before the start of the intervention) and end of the intervention (immediately after the end of the intervention)

**Method of measurement**

Bart's Impulsivity Questionnaire

**2****Description**

assessment of Cognitive functions

**Timepoint**

Beginning of the intervention (before the start of the intervention) and end of the intervention (immediately after the end of the intervention)

**Method of measurement**

Brief Cognitive Rating Scale

**3****Description**

assessment of presence or absence of mood rhythmicity

**Timepoint**

Four hours before the intervention and four hours after the intervention

**Method of measurement**

Mood Rhythm Instrument (MRhI)

**4****Description**

Evaluation of the performance of the reward system (mesocortico limbic circuit)

**Timepoint**

Three hours before the intervention and three hours after the intervention

**Method of measurement**

Functional magnetic resonance imaging

**5****Description**

performance in high-risk decision test (due to reaction time)

**Timepoint**

Three hours before the intervention and three hours after the intervention

**Method of measurement**

Functional magnetic resonance imaging (GO/NO GO task)

**6****Description**

Vulnerability score for substance use and addictive

behaviors test

**Timepoint**

Two hours before the intervention and two hours after the intervention

**Method of measurement**

Vulnerability to substance use and addictive behaviors test

**Secondary outcomes****1****Description**

Impulsivity score in Bart's Impulsivity Questionnaire

**Timepoint**

Beginning of the intervention (before the start of the intervention) and end of the intervention (immediately after the end of the intervention)

**Method of measurement**

Bart's Impulsivity Questionnaire

**2****Description**

assessment of Cognitive functions

**Timepoint**

Beginning of the intervention (before the start of the intervention) and end of the intervention (immediately after the end of the intervention)

**Method of measurement**

Brief Cognitive Rating Scale

**3****Description**

assessment of presence or absence of mood rhythmicity

**Timepoint**

Four hours before the intervention and four hours after the intervention

**Method of measurement**

Mood Rhythm Instrument (MRhI)

**4****Description**

Evaluation of the performance of the reward system (mesocorticolimbic circuit)

**Timepoint**

Three hours before the intervention and three hours after the intervention

**Method of measurement**

Functional magnetic resonance imaging

**5****Description**

performance in high-risk decision test (due to reaction time)

**Timepoint**

Three hours before the intervention and three hours after the intervention

**Method of measurement**

Functional magnetic resonance imaging (GO/NO GO task)

## 6

### Description

Vulnerability score for substance use and addictive behaviors test

### Timepoint

Two hours before the intervention and two hours after the intervention

### Method of measurement

Vulnerability to substance use and addictive behaviors test

## Intervention groups

### 1

#### Description

Intervention group: The intervention for participants lasts for 9 days, the first 3 days are related to getting used to the conditions of the study environment. From the fourth day, the circadian rhythm disturbance protocol will be applied. In the first three days of the study, participants eat breakfast at seven in the morning, lunch at noon and dinner at seven in the evening. From the fourth day, the intervention is as follows: breakfast at seven in the morning, lunch at seven in the afternoon and dinner at twelve at night. Sleep patterns in this group are also planned in such a way that the participants of the intervention group are awake during the night with 450 lux light in the room and are allowed to sleep at eleven o'clock in the morning every day until seven o'clock in the evening with 90 lux light. And research assistants oversee the accurate implementation of this model.

#### Category

Lifestyle

### 2

#### Description

Control group: Participants in the control group are also present on the experimental site for 9 days. The meal times in the control group in all 9 days of presence in the experimental site are as follows: they eat breakfast at seven in the morning, lunch at noon and dinner at seven in the evening, and the patterns of sleeping and waking up are as follows: During the night, between eleven o'clock at night and seven o'clock in the morning, with 0 lux light, they can have a complete and normal night's sleep.

#### Category

Lifestyle

## Recruitment centers

### 1

#### Recruitment center

**Name of recruitment center**

دانشگاه علوم پزشکی شاهرود

**Full name of responsible person**

Mohammad Niroumand Sarvandani

**Street address**

Shahroud University of Medical Sciences and Health Services, Hafte Tir Square, Shahroud, Iran

#### City

Shahroud

#### Province

Semnan

#### Postal code

۳۶۱۴۷-۷۳۹۴۷

#### Phone

+98 23 3239 5054

#### Fax

+98 23 3239 5009

#### Email

info@shmu.ac.ir

#### Web page address

<https://shmu.ac.ir/fa>

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Shahroud University of Medical Sciences

##### Full name of responsible person

Mohammad Hassan Emamian

##### Street address

Shahroud University of Medical Sciences and Health Services, Hafte Tir Square, Shahroud, Iran.

##### City

shahroud

##### Province

Semnan

##### Postal code

3614773955

##### Phone

+98 23 3239 1609

##### Fax

+98 23 3239 1609

##### Email

pishgiri@yahoo.co

##### Web page address

<https://shmu.ac.ir/en>

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Shahroud University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Shahroud University of Medical Sciences

**Full name of responsible person**

Mohammad Niroumand Sarvandani

**Position**

Phd candidate

**Latest degree**

Master

**Other areas of specialty/work**

Neuroscience

**Street address**

No.108,Saman dormitory,Semnan,Shahroud,Iran

**City**

Shahroud

**Province**

Semnan

**Postal code**

3614773955

**Phone**

+98 34 3245 4926

**Fax****Email**

m.niroumand@shmu.ac.ir

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Shahroud University of Medical Sciences

**Full name of responsible person**

Mohammad Niroumand Sarvandani

**Position**

Phd candidate

**Latest degree**

Master

**Other areas of specialty/work**

Neuroscience

**Street address**

No.108,Saman dormitory,Semnan,Shahroud,Iran

**City**

Shahroud

**Province**

Semnan

**Postal code**

3614773955

**Phone**

+98 34 3245 4926

**Fax****Email**

m.niroumand@shmu.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**

Shahroud University of Medical Sciences

**Full name of responsible person**

Mohammad Niroumand Sarvandani

**Position**

Phd candidate

**Latest degree**

Master

**Other areas of specialty/work**

Neuroscience

**Street address**

No.108,Saman dormitory,Semnan,Shahroud,Iran

**City**

Shahroud

**Province**

Semnan

**Postal code**

3614773955

**Phone**

+98 34 3245 4926

**Fax****Email**

m.niroumand@shmu.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

All personal data of the participants will share without name and personal information (unidentified)

**When the data will become available and for how long**

the access period start 6 months after results publication

**To whom data/document is available**

researcher who are working in academic and scientific institutions

**Under which criteria data/document could be used**

the use of all data or documents for researcher for using in their research with reference to the source is allowed

**From where data/document is obtainable**

To researcher of this study,Mohammad Niroumand Sarvandani refer to email address:  
m.niroumand@shmu.ac.ir

**What processes are involved for a request to access data/document**

by sending an email to m.niroumand@shmu.ac.ir. all the demanded files will be provided to the applicant within 10 working days

**Comments**